Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Epic Ink Deal to Integrate Genomic Tests Into EMR Network

NEW YORK – Foundation Medicine announced on Thursday a partnership to integrate its testing services with Epic Systems' electronic medical record system.

Under the deal, Foundation's comprehensive genomic profiling test, along with other testing services, will be available for physicians within the Epic network to order electronically. Clinicians will also be able to receive and review results directly within their existing workflow.

Financial and other terms of the deal were not disclosed.

The partnership is intended to support oncology practices, academic medical centers, and other health systems "by providing easy access to clinical and genomic information in one place to better enable more streamlined clinical decision-making," Foundation said in a statement.

It is also designed to reduce data entry, the Roche subsidiary said. The integration is expected to be available next year. Foundation is also partnering with health systems using other EMR systems to create custom solutions for those practices, it said.

In July, Foundation announced a deal with Flatiron Health to make comprehensive genomic profiling tests available through Flatiron's OncoEMR platform.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.